ProFunds

Ticker
Investor Class
BIPIX
Service Class
BIPSX

CUSIP
Investor Class
743185-480
Service Class
743185-472

Fund Number
Investor Class
043
Service Class
073

Inception Date
6/19/2000

View Proxy
Votes

Biotechnology UltraSector ProFund

Vital Statistics

Class	Ticker	CUSIP	Fund Number
Investor	BIPIX	743185-480	043
Service	BIPSX	743185-472	073

Inception Date for all share classes is 6/19/2000

NAV

as of 11/6/2009

Class	NAV	% Change	$ Change
Investor	$50.38	1.88%	$0.93
Service	$46.01	1.86%	$0.84

At a GlanceThe Biotechnology UltraSector ProFund provides leveraged exposure to the Dow Jones U.S. Biotechnology Index. ObjectiveSeeks daily investment results, before fees and expenses, that correspond to 150%, of the daily performance of the Dow Jones U.S. Biotechnology Index.

There is no guarantee that any ProFund will achieve its investment objective. Investment return and principal value will vary and shares may be worth more or less at redemption than at original purchase. See the prospectus for more information.

This ProFund routinely employs leveraged investment techniques that magnify gains and losses and result in greater volatility in value.

This ProFund invests in a single industry. Its shares do not represent a complete investment program. As non-diversified and single industry fund, the value of its shares may fluctuate more than shares invested in a broader range of industries and companies.

Dow Jones U.S. Biotechnology Index

The Dow Jones U.S Biotechnology Index measures the performance of the biotechnology industry of the U.S. equity market. Component companies include those engaged in genetic research, and/or the marketing and development of recombinant DNA products. Makers of artificial blood and contract biotechnology researchers are also included in the Index. It is not possible to invest directly in an index.

Index (as of 9/30/2009)

Top 10 Index Companies

Name	Weight
Amgen Inc.	27.90%
Gilead Sciences Inc.	19.40%
Celgene Corp.	11.77%
Genzyme Corp.	7.02%
Biogen Idec Inc.	6.67%
Life Technologies Corp.	3.76%
Vertex Pharmaceuticals Inc.	3.13%
Illumina Inc.	2.41%
Alexion Pharmaceuticals Inc.	1.79%
Dendreon Corp.	1.48%

Total Index Companies

Average Index Market Capitalization

7.05 billion

Returns (as of 9/30/2009)

Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed may be worth more or less than the original cost. For standardized returns as of the most recent month-end, click here.

Returns include the reinvestment of dividends and capital gains.

YTD (as of 11/6/2009)	-0.22%
Average Annual One Year	-6.58%
Average Annual Three Year	0.44%
Average Annual Five Year	5.82%
Average Annual Ten Year	––
Average Annual Since Inception	-6.30%
Cumulative Since Inception	-45.33%
Gross Expense Ratio	1.60%
Net Expense Ratio	––

View Daily Price Movement Performance Chart

Fund Statistics

Limits On Exchanges	None
Minimum Investment
Individual Investor	$15,000
Financial Professionals	$5,000

All data, unless otherwise noted, is as of 9/30/2009 and for Investor Class Shares only and is subject to change.

07-00291

Investing in ProFunds involves certain risks, including in all or some cases, leverage, liquidity, concentration, non-diversification, foreign investment, foreign currency, high yield, interest rate, credit, market, correlation, aggressive investment technique and repurchase agreement risks. Moreover, there is no guarantee that any ProFund will achieve its investment objective. These risks can increase volatility and decrease performance. All ProFunds permit active investment strategies which can decrease performance and increase expenses.

I want to...

› Open an account

› Get prospectus/fund
reports

Quick links

› Download ProFunds
Quickfacts

› NAVs for all funds

› Returns for all funds

› See Fund Distributions

› Historical NAVs

› Tickers/CUSIPS for all
funds

› ProCharts

Many ProFunds routinely employ leveraged investment techniques that magnify gains and losses and result in greater volatility in value. Each leveraged or inverse ProFund seeks a return that is a multiple (e.g., 200%) of the return of an index or other benchmark (target) for a single day. Due to the compounding of daily returns, leveraged and inverse ProFunds' returns over periods other than one day will likely differ in amount and possibly direction from the target return for the same period. Investors should monitor holdings consistent with their strategies, as frequently as daily. For more on correlation, leverage and other risks, please read the prospectus.

All ProFunds are subject to active investor risk. There are no restrictions on the size and frequency of trades and no transaction fees. The frequent exchanges our policies permit can decrease performance, increase expenses and incur tax consequences. All ProFunds permit active investment strategies that can decrease performance and increase expenses. In addition, it is important to note that some ProFunds are not suitable for all investors, because of aggressive investment techniques many of the funds employ.

"ProFunds Group" includes ProFunds mutual funds and ProShares ETFs. ProFunds are distributed by ProFunds Distributors, Inc., member FINRA.

Carefully consider the investment objectives, risks, charges and expenses of ProFunds before investing or sending money. This and other information can be found in their prospectuses. Read the prospectus carefully before investing. For a ProFunds prospectus, please call 888-PRO-FNDS (888-776-3637), or visit www.profunds.com. Financial professionals should call 888-PRO-5717 (888-776-5717).

Legal Information